Chinese ADC, RNA Therapy Developers Lead May/June Fundraising
Emerging companies including Bliss Biopharmaceutical, Coherent Biopharma and WestGene Biopharma lifted China biotech funding from May to mid-June.
You may also be interested in...
China's BlissBio has unveiled new clinical results for its HER2-targeting ADC BB-1701 in HER2-low breast cancer, which showed “promising” preliminary efficacy and "manageable" safety, in a glimpse into the Enhertu challenger's potential.
The Japanese drug maker is the second in the space of a month to partner up with a Chinese biotech firm for a HER2-targeting antibody-drug conjugate, as ADCs gain more interest from large pharma firms.
Brian Yang, Dexter Yan and guest speaker Kevin Grogan from the UK discuss Shanghai's latest policy to spur biopharma investment, the US House's recent draft bill to restrict bio service providers from China, and multinationals' strategies in China and views on Chinese innovation.